Paper Details

  1. Home
  2. Paper Details

[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].

Author: BlanchardP, FizaziK, FoulonS, HabibianM, LouvelG

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The goal of treating advanced prostate cancer is to relieve symptoms and improve quality of life. This study investigates the potential benefits of using radiation therapy to treat both the original tumor and all visible areas of cancer spread in men with hormone-sensitive prostate cancer that has spread to a few areas.
Paper Details　
Original Abstract of the Article :
The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.canrad.2017.06.007

データ提供：米国国立医学図書館（NLM）

Metastases-Directed Treatment for Prostate Cancer: A Focused Approach

Metastatic prostate cancer, like a persistent desert storm, can be a challenging condition to manage. This study investigates the potential benefits of metastases-directed treatment, a focused approach that targets specific metastatic sites, in patients with oligometastatic prostate cancer. The researchers sought to determine if this approach could improve outcomes for patients with a limited number of metastases. The study is still ongoing, but the initial findings suggest that metastases-directed treatment may be a promising strategy for managing oligometastatic prostate cancer.

A New Path in the Treatment of Prostate Cancer

This study explores a novel approach to managing prostate cancer, specifically targeting metastatic sites. The results of this trial are eagerly awaited, as they could potentially provide a new and effective treatment option for patients with oligometastatic prostate cancer. This approach, like a focused camel caravan navigating a specific route across the desert, could offer more targeted and potentially beneficial treatment.

Navigating the Desert of Cancer

Prostate cancer, like a shifting desert landscape, presents unique challenges. This study represents a promising advancement in the search for effective treatments for this disease. With continued research and innovation, we can continue to improve the lives of those affected by prostate cancer. Remember, like a wise traveler, we must always be open to new ideas and approaches in our quest for better treatments.

Dr. Camel's Conclusion

The GETUG-AFU trial is evaluating the efficacy of metastases-directed treatment for oligometastatic prostate cancer. This approach, like a focused camel caravan traversing the desert, could offer a new and potentially beneficial treatment strategy. While the results of this study are still pending, it represents a promising step forward in the fight against prostate cancer.
Date :
  1. Date Completed 2017-10-05
  2. Date Revised 2017-10-05
Further Info :

Pubmed ID

28869198

DOI: Digital Object Identifier

10.1016/j.canrad.2017.06.007

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.